Literature DB >> 29851752

Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma.

Chen Liu, He Cheng, Kaizhou Jin, Meng Guo, Yu Lu, Zhengshi Wang, Chao Yang, Jiang Long, Quanxing Ni, Xianjun Yu, Guopei Luo.   

Abstract

OBJECTIVES: Notable modifications have been made in the American Joint Committee on Cancer (AJCC) Staging eighth edition staging for pancreatic cancer for the consideration of the irreproducible and inapplicable of the AJCC seventh edition staging. However, the new staging classification has not been systemically verified.
METHODS: A comparison was performed to evaluate the application of the AJCC seventh and eighth staging classifications using the Surveillance, Epidemiology, and End Results registry (18,450 patients) and an institutional series (2040 patients).
RESULTS: For the eighth staging classification, patients with tumor diameter of greater than 4 cm (T3N0M0, IIA) had similar prognosis to patients with 1 to 3 positive nodes (T1-3N1M0, IIB). For patients who underwent tumor resection and without lymph node involvement, survival curves of T1 (≤2 cm), T2 (2-4 cm), and T3 (>4 cm) were well separated. Statistical difference in survival analyses was demonstrated in N0 (0 positive node), N1 (1-3 positive nodes), and N2 (≥4 positive nodes) patients underwent tumor resection. The AJCC eighth edition had better stage distribution than the AJCC seventh edition for pancreatic cancer.
CONCLUSIONS: The eighth edition of AJCC staging is more applicable and accurate than the seventh edition for pancreatic adenocarcinoma.

Entities:  

Mesh:

Year:  2018        PMID: 29851752     DOI: 10.1097/MPA.0000000000001073

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

1.  The American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma: is it better than the 7th edition?

Authors:  Dong Woo Shin; Jaihwan Kim
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

2.  Tumour Size and T-Stage in Pancreatic Cancer Resection Specimens Depend on the Pathology Examination Approach.

Authors:  My Linh Tran; Maia Blomhoff Holm; Caroline Sophie Verbeke
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

3.  Magnetic resonance imaging for preoperative staging of pancreatic cancer based on the 8th edition of AJCC guidelines.

Authors:  Yan Deng; Bing Ming; Jia-Long Wu; Ting Zhou; Shi-Yong Zhang; Yong Chen; Chuan Lan; Xiao-Ming Zhang
Journal:  J Gastrointest Oncol       Date:  2020-04

4.  Whipple Grossing in the Era of New Staging: Should We Standardize?

Authors:  Jiaqi Shi; Olca Basturk
Journal:  Diagnostics (Basel)       Date:  2019-09-29

5.  Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy.

Authors:  Chen Liu; He Cheng; Kaizhou Jin; Zhiyao Fan; Yitao Gong; Yunzhen Qian; Shengming Deng; Qiuyi Huang; Quanxing Ni; Xianjun Yu; Guopei Luo
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

6.  Peripheral blood monocytes predict clinical prognosis and support tumor invasiveness through NF-κB-dependent upregulation of Snail in pancreatic cancer.

Authors:  Shaojie Chen; Feifei Huang; Chong He; Jiajia Li; Shangxiang Chen; Yaqing Li; Yinting Chen; Guoda Lian; Kaihong Huang
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

Review 7.  A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer.

Authors:  Christian Chapa-González; Karina López; Kimberly Michelle Lomelí; Jorge Alberto Roacho-Pérez; Jazmín Cristina Stevens
Journal:  Life (Basel)       Date:  2022-02-22

8.  The eighth version of American Joint Committee on Cancer nodal classification for high grade pancreatic neuroendocrine tumor should be generalized for the whole population with this disease.

Authors:  Mu-Xing Li; Hang-Yan Wang; Chun-Hui Yuan; Chao-Lai Ma; Bin Jiang; Lei Li; Li Zhang; Hong Zhao; Jian-Qiang Cai; Dian-Rong Xiu
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.